HROW Stock Analysis: Buy, Sell, or Hold?
HROW - Harrow, Inc. Common Stock
$40.94
-0.99 (-2.36%)
▼
5d:
-7.94%
30d:
-18.15%
90d:
+11.31%
HOLD
LOW Confidence
Last Updated: January 30, 2026
Earnings: Mar 26, 2026
Get Alerted When HROW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called HROW this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HROW shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HROW shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$89.42
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$55.53
26.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HROW is currently trading at $40.94, which is considered oversold relative to its 30-day fair value range of $44.28 to $51.21. From a valuation perspective, the stock is trading at a discount (Forward PE: 18.7) compared to its historical average (21.0). Remarkably, the market is currently pricing in an annual earnings decline of 3.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, HROW is in a uptrend. The price is currently testing key support at $40.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $70.62 (+72.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HROW is in a uptrend. The price is currently testing key support at $40.61. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (4th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $70.62 (+72.5%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$44.28 -
$51.21
Company Quality Score
55/100
(HOLD)
Options IV Signal
4th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
83.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 4th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 72.5% below Wall St target ($70.62)
- CAUTION: Recommendation downgraded due to -7.9% 5-day decline
Fair Price Analysis
30-Day Fair Range
$44.28 -
$51.21
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$4.16
(10.1%)
Support & Resistance Levels
Support Level
$40.61
Resistance Level
$50.17
Current Trend
Uptrend
Fundamental Context
Forward P/E (Next Year Est.)
18.72
Wall Street Target
$70.63
(+72.5%)
Revenue Growth (YoY)
45.4%
Earnings Growth (YoY)
-64.0%
Profit Margin
-2.0%
Valuation Discount vs History
-3.7% cheaper
PE vs Historical
18.7 vs 21.0
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-3.7%
(market-implied from PE analysis)
1-Year Target
$39.43
(-4%)
2-Year Target
$37.97
(-7%)
3-Year Target
$36.56
(-11%)
3-Yr Target (if PE normalizes)
(PE: 19→21)
$41.01
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 254.6%)
$164.58
(+302%)
Base:
(SPY PE: 18.7, Growth: 254.6%)
$138.17
(+238%)
Bear:
(PE: 15.9, Growth: 254.6%)
$117.45
(+187%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 18.7 to 21.0
Stabilization Target:
$45.92
(+12.2%)
PE Expansion Potential:
+12.2%
Last updated: February 01, 2026 11:06 PM ET
Data refreshes hourly during market hours. Next update: 12:06 AM
Data refreshes hourly during market hours. Next update: 12:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HROW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 62 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
14 analysts |
$21 | 57 HOLD |
